Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

Author:

de Zeeuw Dick1,Heerspink Hiddo J L1

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands

Abstract

Abstract The current guideline treatment for patients with diabetes and nephropathy to lower the high risk of renal and cardiovascular (CV) morbidity and mortality is based on results of clinical studies that have tested new drugs in large groups of patients with diabetes and high renal/CV risk. Although this has delivered breakthrough therapies like angiotensin receptor blockers, the residual renal/CV risk remains extremely high. Many subsequent trials have tried to further reduce this residual renal/CV risk, without much success. Post hoc analyses have indicated that these failures are, at least partly, due to a large variability in response between and within the patients. The current ‘group approach’ to designing and evaluating new drugs, as well as group-oriented drug registration and guideline recommendations, does not take this individual response variation into account. Like with antibiotics and cancer treatment, a more individual approach is warranted to effectively optimize individual results. New tools to better evaluate the individual risk change have been developed for improved clinical trial design and to avoid trial failures. One of these tools, the composite multiple parameter response efficacy score , is based on monitoring changes in all available risk factors and integrating them into a prediction of ultimate renal and CV risk reduction. This score has also been modelled into a clinical decision support system for use in monitoring and changing the therapy in individual patients to protect them from renal/CV events. In conclusion, future treatment of renal/CV risk in diabetes should transition from an era of ‘one size fits all’ into the new era of ‘a fit for each size’.

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3